Archive
AstraZeneca gets shot in the arm from Deutsche
Drugs giant AstraZeneca gets a shot in the arm from broker heavyweight Deutsche today...
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 53 of 55
Investments and investor services
FTSE 100 swings to 35 point loss
After lunch, investors were not willing to carry much risk into the American session.
Investments and investor services
Risers & Fallers: AstraZeneca, Horizonte Minerals, Active Energy, Regency Mines, KAZ Minerals...
Below are the main news-driven share price movements at 4pm.
Investments and investor services
Crest Nicholson is Goldman's top pick in midst of housing sector's results season
It seems the housing sector has been bouncing back since the current decade began, but brokers seem to agree there is further to go.
AstraZeneca gets new FDA approval for heart drug
Patients can now be given the drug for more than twelve months
Archive
Time to jump on Merlin shares, reckons UBS
Attractions and park operator Merlin Entertainments' share price is now at an attractive level, says Swiss broker UBS...
Woodford fund proving a summer favourite for investors
Bio and pharma holdings keep Woodford on top with other healthcare funds also doing well.
Valeant Pharmaceuticals licenses psoriasis drug from AstraZeneca
After Amgen, the originator of the skin condition treatment, abandoned brodalumab, Astra has called on the Canadian dermatology specialist to develop the drug.
AstraZeneca licenses psoriasis rights to Valeant
After Amgen, the originator of the skin condition treatment, abandoned brodalumab, Astra has called on the Canadian dermatology specialist to develop the drug.
AstraZeneca nabs rival's executive
Dr Sean Bohen is joining on September 15 from Genentech, a Roche subsidiary.
FTSE 100 plummets as China sell-off spooks markets
In the UK, the FTSE 100 was more than 2% lower, 135 points, to 6,051 with not a single constituent managing to eke out a gain.
FTSE 100 has £80bn wiped off on Black Monday
On what some are calling ‘Black Monday’ the FTSE 100 was hit to the tune of £80bn, suffering its worst day since 2009.
Eli Lilly advances after positive results in diabetes study
Shares in Eli Lilly were among the few blue-chips making headway on Thursday after a positive result in a diabetes study.
Analysis: Old vs new, Witan and Woodford release interims
Witan one of the UK’s oldest investment trusts, and Woodford Patient Capital Trust, which listed in April, reported first half figures today
AstraZeneca to pay Inovio Pharma $727 mln to produce cancer vaccine
It is AstraZeneca's third deal in less than a week
Investments and investor services
FTSE 100 flies as Glaxo becomes latest subject of bid gossip
The latest pharma bid rumour to surface is Pfizer gunning for Glaxo, but it was the miners that drove Footsie's ascent
Analysis: Shire dreaming big with Baxalta offer
Baxalta’s board has already shot down the deal as it has refused to enter into talks on the offer but Shire isn’t about to bow out without a fight.
FTSE 100 buoyed by miners and more pharma bid gossip
Rio Tinto led the advance ahead of results due out tomorrow